Tissue-based compositions and methods of use thereof

Abstract

Compositions comprising extracellular matrix (ECM) materials and methods of use thereof are disclosed. The compositions may comprise two or more ECM materials derived from different types of tissues, such as, e.g., lung tissue and spleen tissue, formulated for administration to a patient or configured as a medical device for implantation in or application to the patient. The compositions may combine complementary properties of different types of ECM materials for customized patient-specific and/or site-specific tissue repair and/or regeneration.

1 - 30 . (canceled) 
     
     
         31 . A composition comprising:
 spleen extracellular matrix in particulate form, wherein the spleen extracellular matrix comprises native growth factors retained from spleen tissue;   a second extracellular matrix other than spleen extracellular matrix in particulate form; and   a carrier in liquid or gel form;   wherein the composition is formulated for application onto or into a site of defect or wound of a patient.   
     
     
         32 . The composition of  claim 31 , wherein the carrier comprises a third extracellular matrix in gel form, the third extracellular matrix being chosen from spleen extracellular matrix, lung extracellular matrix, gall bladder extracellular matrix, bone marrow extracellular matrix, pancreatic extracellular matrix, or liver extracellular matrix. 
     
     
         33 . The composition of  claim 31 , wherein the carrier comprises hyaluronic acid, gelatin, lecithin, collagen gel, or saline. 
     
     
         34 . The composition of  claim 31 , wherein the spleen extracellular matrix comprises at least two native growth factors retained from spleen tissue chosen from vascular endothelial growth factor, platelet-derived growth factor, epidermal growth factor, fibroblast growth factor, and insulin-like growth factor. 
     
     
         35 . The composition of  claim 31 , further comprising at least one of tricalcium phosphate, hydroxyapatite, bioactive glass, mineralized bone, or demineralized bone. 
     
     
         36 . The composition of  claim 31 , further comprising at least one of an antimicrobial agent or a pharmaceutical agent. 
     
     
         37 . The composition of  claim 31 , formulated as a coating of an implantable medical device or formulated for injection into the site of defect or wound of the patient. 
     
     
         38 . A composition comprising:
 spleen extracellular matrix in particulate form, wherein the spleen extracellular matrix comprises at least two native growth factors retained from spleen tissue chosen from vascular endothelial growth factor, platelet-derived growth factor, epidermal growth factor, fibroblast growth factor, and insulin-like growth factor;   lung extracellular matrix in particulate form; and   a carrier comprising a third extracellular matrix in gel form;   wherein the composition is formulated for injection into a site of defect or wound of a patient.   
     
     
         39 . The composition of  claim 38 , wherein the particles of the spleen extracellular matrix range from about 100 nm to about 2000 μm in diameter. 
     
     
         40 . The composition of  claim 38 , wherein the particles of the spleen extracellular matrix range from about 50 μm to about 100 μm in diameter. 
     
     
         41 . The composition of  claim 38 , wherein the particles of the spleen extracellular matrix or the particles of the lung extracellular matrix have a bimodal size distribution. 
     
     
         42 . A method for treating a patient, comprising:
 delivering a composition to a site of defect or wound of the patient, wherein the composition comprises:
 spleen extracellular matrix in particulate form, wherein the spleen extracellular matrix retains native growth factors of spleen tissue; 
 a second extracellular matrix other than spleen extracellular matrix in particulate form; and 
 a carrier in liquid or gel form. 
   
     
     
         43 . The method of  claim 42 , wherein the carrier comprises a third extracellular matrix in gel form, the third extracellular matrix being chosen from spleen extracellular matrix, lung extracellular matrix, gall bladder extracellular matrix, bone marrow extracellular matrix, pancreatic extracellular matrix, or liver extracellular matrix. 
     
     
         44 . The method of  claim 42 , wherein the particles of the spleen extracellular matrix range from about 50 μm to about 100 μm in diameter, and wherein the spleen extracellular matrix comprises at least two native growth factors retained from spleen tissue chosen from vascular endothelial growth factor, platelet-derived growth factor, epidermal growth factor, fibroblast growth factor, and insulin-like growth factor. 
     
     
         45 . The method of  claim 42 , wherein the composition further comprises at least one of tricalcium phosphate, hydroxyapatite, bioactive glass, mineralized bone, or demineralized bone. 
     
     
         46 . The method of  claim 42 , wherein the composition is injected into a joint of the patient. 
     
     
         47 . The method of  claim 42 , wherein the composition is injected into cartilage, a tendon, or a ligament of the patient. 
     
     
         48 . The method of  claim 42 , wherein the composition is delivered to one or more sites along a nerve that has been damaged or sustained loss of a myelin sheath of the nerve. 
     
     
         49 . The method of  claim 42 , wherein the composition is injected into myocardial tissue of the patient. 
     
     
         50 . The method of  claim 42 , wherein the composition is delivered to an eye of the patient.